Dennis Lai-Hong Cheong1, Bo Zhang1, Bingwen Zheng1, Limiao Jiang1, Eugene Wai Mun Ong2, Soo Chin Lee3,4, and Thian C Ng1
1Clinical Imaging Research Centre, A*STAR-NUS, Singapore, Singapore, 2Department of Diagnostic Imaging, National University Hospital in Singapore, Singapore, Singapore, 3Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore, 4Cancer Science Institute of Singapore, Singapore, Singapore
Synopsis
Higher resolution DCE-MRI is readily attainable and should allow for
more realistic distributed parameter tracer kinetics models to be used.
However, simpler, faster and lesser parameters compartmental models such as the
modified Tofts model are still preferred by many researchers. We present here
how we have implemented a distributed parameter model to analyze 2.4sec/frame DCE MRI data in a clinical trial of neo-adjuvant chemotherapy with or
without short-course anti-angiogenic therapy in breast cancer patients. The results from modified Tofts and the distributed parameter
model differ. More realistic distributed parameter models might be better in
analyzing high temporal resolution DCE-MRI data.Introduction
Dynamic Contrast-Enhanced (DCE) MRI has
been widely used to assess breast tumor microvasculature. Temporal resolution
has reduced from above a minute, which are multiple high spatial resolution
post-contrast acquisitions, to about 4s, which is considered very fast. Analysis
methods range from qualitative visual inspection of signal intensity time
curves, to semi-quantitative parameters such as time to peak and uptake slope
of intensity or tracer concentration time curves (C(t)), and to quantitative
tracer kinetics (TK) analysis. Compartmental models are more commonly used for
quantitative analysis while more realistic distributed parameter (DP) models
1 are less commonly used. Here, we report on high temporal resolution DCE-MRI
analyzed with both types of TK models in a clinical trial that assess early
chemotherapy response with or without anti-angiogenesis pre-treatment, in
breast cancer.
Methods
Sixty-four
newly diagnosed breast cancer patients in an on-going clinical trial who were scheduled
to receive neo-adjuvant chemotherapy (doxorubicin/cyclophosphamide
(AC)), were randomly assigned to receive an
additional low-dose (oral Sunitinib (Su) at 12.5mg/d) short-duration (7 days) anti-angiogenesis pre-treatment (ARM-B) or
not (ARM-A)2. DCE-MRI data were acquired at these time points: before
anti-angiogenic pre-treatment using Sunitinib, before and after first cycle of
chemotherapy.
MRI scans were
performed on a whole-body 3T MRI (Magnetom Trio; Siemens, Germany) with a
seven-channel breast receiver coil and an additional surface coil placed on their
back for better imaging of the descending aorta. Axial DCE-MRI were scanned in
the prone position with a spoiled 3D FLASH acquisition (TR=4ms, flip angle
(FA)=15°, matrix=128×128, 16x4mm slices to cover whole tumor, temporal
resolution=2.4s/f). T1 maps were acquired with variable FA (FAs=5°/13°/20°,
TR=20ms) for computation of tracer concentrations. B1 maps were acquired using
the system RF sequence for B1 correction.
Both the modified Tofts
(mT) and 2-comparment DP models1 were used to analyze the DCE data. AIF is
measured from the fourth inferior slice at the descending aorta to reduce
in-flow effects. A physiological based AIF model3 was fitted to the AIF data
and later used in the fitting of the tissue C(t). This allows AIF
arrival time to be adjusted freely while fixing the TK impulse response
function (IRF) to always start at time 0 to overcome the issue with
discontinuity at the bolus arrival time. Discontinuity issue at the mean
vascular transit time (tp in Figure 1 right) the DP model is handled
by up-sampling of AIF and IRF by 10 times, before applying the correction
method by Koh et al.4 Using an analytical AIF form further smooths the
search surface during curve fitting. All processing were performed on MatLab,
where the expansion series form of the DP model5 was implemented for faster
computation.
Results
Figure 1 shows
typical AIF and tissue C(t). The high temporal resolution clearly captured the
first bolus and a second smaller peak in the AIF. Our AIF model managed to fit
the AIF data appropriately. We notice the scaled AIF in the mT model did not
match the initial part of many tissue C(t) (Figure 1 centre). The K
trans and
permeability surface-area product (PS) maps (Figure 2) were similar but
differed in values. Table 1 shows the results from 48 patients who had
completed all scans. All parameters did not show any significant difference in
ARM-A. In ARM-B, fractional plasma volume (v
p) and fractional extravascular
extracellular volume (v
e) in the mT model showed more changes than v
p and v
e in
the DP model (circles in Table 1). However, DP permeability measures (PS,
K
trans (see below) and first pass extraction ratio (E)) showed significant changes at
post-AC while mT K
trans did not. Perfusion (F) measured by DP showed no
significant changes between all scans. The K
trans in DP model is defined as E×F.
Discussion
We have performed high
temporal resolution DCE MRI of breast cancer and analyzed the data with more
realistic DP and the commonly used mT models. The initial AIF features captured
in our data illustrated a misfit issue (Figure 1 centre) in the mT model.
Although permeability measures from both models showed similar trend, mT K
trans
and v
e were much higher than those of DP model. Since mT K
trans also contains
perfusion contributions, and there was no significant changes in the perfusion
as measured by DP F, we suspect this could have muddled the values in mT K
trans
to not reflecting significant changes in permeability while all three
permeability measures of DP model have.
Conclusion
The difference between mT and DP models is
noticed in analyzing high temporal resolution. More realistic distributed
parameter models might be better in analyzing high temporal resolution DCE MRI
data.
Acknowledgements
This study is supported by grants NMRC/CSI/0015/2009
(SCL) and R-180-000-016-733 (TCN).References
1. Koh TS et al. Fundamentals of Tracer Kinetics for Dynamic Contrast-Enhanced MRI. JMRI 2011
34:1262-76.
2.
Ng TC et al.
Dynamic-Contrast-Enhanced MRI and Dynamic Tensor
Imaging (DTI) for the Early Detection of Anti-angiogenic Effect and Vessel
“Normalization” in Human Breast Cancer Treated with Neoadjuvant Chemotherapy.
Proc. ISMRM 2015:0605.
3. Cheong DLH and Ng
TC. Proc. ISMRM. A physiological model for injected contrast agent
concentration incorporating recirculation, extravasation and excretion
2013:3063
4. Koh TS, Cheong DLH
and Hou Z. MRM. Issues of Discontinuity in the Impulse Residue Function for
Deconvolution Analysis of Dynamic Contrast-Enhanced MRI Data. MRM 2011 66:886-892.
5. Koh TS. On the a Priori Identifiability of the
Two-Compartment Distributed Parameter Model From Residual Tracer Data Acquired
by Dynamic Contrast-Enhanced Imaging. IEEE Trans. Biomed. Eng. 2008 55:340-344.